Effects on interaction kinetics of mutations at the VH–VL interface of Fabs depend on the structural context

The influence of framework residues belonging to VH and VL modules of antibody molecules on antigen binding remains poorly understood. To investigate the functional role of such residues, we have performed semi‐conservative amino acid replacements at the VH–VL interface. This work was carried out with (i) variants of the same antibody and (ii) with antibodies of different specificities (Fab fragments 145P and 1F1h), in order to check if functional effects are additive and/or similar for the two antibodies. Interaction kinetics of Fab mutants with peptide and protein antigens were measured using a BIACORE® instrument. The substitutions introduced at the VH–VL interface had no significant effects on ka but showed small, significant effects on kd. Mutations in the VH module affected kd not only for the two different antibodies but also for variants of the same antibody. These effects varied both in direction and in magnitude. In the VL module, the double mutation FL37L–QL38L, alone or in combination with other mutations, consistently decreased kd about two‐fold in Fab 145P. Other mutations in the VL module had no effect on kd in 145P, but always decreased kd in 1F1h. Moreover, in both systems, small‐magnitude non‐additive effects on kd were observed, but affinity variations seemed to be limited by a threshold. When comparing functional effects in antibodies of different specificity, no general rules could be established. In addition, no clear relationship could be pointed out between the nature of the amino acid change and the observed functional effect. Our results show that binding kinetics are affected by alteration of framework residues remote from the binding site, although these effects are unpredictable for most of the studied changes. Copyright © 2000 John Wiley & Sons, Ltd.

[1]  M. V. Van Regenmortel,et al.  Concentration measurement of unpurified proteins using biosensor technology under conditions of partial mass transport limitation. , 1997, Analytical biochemistry.

[2]  J. Sharon Structural correlates of high antibody affinity: three engineered amino acid substitutions can increase the affinity of an anti-p-azophenylarsonate antibody 200-fold. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[3]  E. Getzoff,et al.  Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: proposal of a structural mechanism. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[4]  G. K. Ackers,et al.  Long-range, small magnitude nonadditivity of mutational effects in proteins. , 1995, Biochemistry.

[5]  I. Pastan,et al.  Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv. , 1998, Journal of molecular biology.

[6]  E. Weiss,et al.  Bacterially expressed Fabs of monoclonal antibodies neutralizing tumour necrosis factor alpha in vitro retain full binding and biological activity. , 1993, Molecular Immunology.

[7]  B. Sandmaier,et al.  Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency. , 1998, Biophysical journal.

[8]  D Altschuh,et al.  Functional mapping of conserved residues located at the VL and VH domain interface of a Fab. , 1996, Journal of molecular biology.

[9]  G. Winter,et al.  Antibody framework residues affecting the conformation of the hypervariable loops. , 1992, Journal of molecular biology.

[10]  T. Teeri,et al.  Efficient secretion of murine Fab fragments by Escherichia coli is determined by the first constant domain of the heavy chain. , 1993, Gene.

[11]  C. Yanisch-Perron,et al.  Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. , 1985, Gene.

[12]  J. Xiang,et al.  Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops. , 1995, Journal of molecular biology.

[13]  A R Rees,et al.  A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing. , 1996, Protein engineering.

[14]  C Chothia,et al.  Structural determinants in the sequences of immunoglobulin variable domain. , 1998, Journal of molecular biology.

[15]  D. Altschuh,et al.  Kinetic analysis of the effect on Fab binding of identical substitutions in a peptide and its parent protein. , 1999, Biochemistry.

[16]  S. Ho,et al.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction. , 1989, Gene.

[17]  Andrew D. Griffiths,et al.  By–Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling , 1992, Bio/Technology.

[18]  G. Adams,et al.  Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. , 1996, Journal of molecular biology.

[19]  T C Terwilliger,et al.  Engineering multiple properties of a protein by combinatorial mutagenesis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[20]  I M Gelfand,et al.  Analysis of the relation between the sequence and secondary and three-dimensional structures of immunoglobulin molecules. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[21]  H. Bedouelle,et al.  Functional characterization of the somatic hypermutation process leading to antibody D1.3, a high affinity antibody directed against lysozyme. , 1999, Journal of immunology.

[22]  T. Kunkel Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Horovitz,et al.  Double-mutant cycles: a powerful tool for analyzing protein structure and function. , 1996, Folding & design.

[24]  L. Presta,et al.  Antibody Humanization Using Monovalent Phage Display* , 1997, The Journal of Biological Chemistry.

[25]  R A Goldstein,et al.  Mutation matrices and physical‐chemical properties: Correlations and implications , 1997, Proteins.

[26]  D R Burton,et al.  CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. , 1995, Journal of molecular biology.

[27]  J. Briand,et al.  A major part of the polypeptide chain of tobacco mosaic virus protein is antigenic , 1985, The EMBO journal.

[28]  D. Altschuh,et al.  Comparative interaction kinetics of two recombinant fabs and of the corresponding antibodies directed to the coat protein of tobacco mosaic virus , 1996, Journal of molecular recognition : JMR.

[29]  G. Cheetham,et al.  Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart. , 1998, Journal of molecular biology.

[30]  L. Presta,et al.  Humanization of an antibody directed against IgE. , 1993, Journal of immunology.

[31]  J W Smith,et al.  High-affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Huibregtse,et al.  Mechanism of HPV E6 proteins in cellular transformation. , 1996, Seminars in cancer biology.

[33]  M. Tsuchiya,et al.  Humanization of mouse ONS-M21 antibody with the aid of hybrid variable regions. , 1995, Molecular immunology.

[34]  G Schreiber,et al.  Energetics of protein-protein interactions: analysis of the barnase-barstar interface by single mutations and double mutant cycles. , 1995, Journal of molecular biology.

[35]  D. Altschuh,et al.  Cooperative effects of mutations in a recombinant Fab on the kinetics of antigen binding. , 1997, Molecular immunology.